FR2459046A1 - Procede de preparation de solutions aqueuses stables d'alloxane et solutions en resultant - Google Patents
Procede de preparation de solutions aqueuses stables d'alloxane et solutions en resultant Download PDFInfo
- Publication number
- FR2459046A1 FR2459046A1 FR7915363A FR7915363A FR2459046A1 FR 2459046 A1 FR2459046 A1 FR 2459046A1 FR 7915363 A FR7915363 A FR 7915363A FR 7915363 A FR7915363 A FR 7915363A FR 2459046 A1 FR2459046 A1 FR 2459046A1
- Authority
- FR
- France
- Prior art keywords
- alloxane
- preparation
- aqueous solutions
- reducing sugar
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 239000000243 solution Substances 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000008569 process Effects 0.000 title claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 title claims abstract description 6
- 235000000346 sugar Nutrition 0.000 claims description 15
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical group OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- 239000003708 ampul Substances 0.000 claims description 5
- 229960002737 fructose Drugs 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZIIHZVKHFWOENY-UHFFFAOYSA-N 5,5-dihydroxy-1,3-diazinane-2,4,6-trione Chemical compound OC1(O)C(=O)NC(=O)NC1=O ZIIHZVKHFWOENY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- -1 alloxane tetrahydrate Chemical class 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7915363A FR2459046A1 (fr) | 1979-06-15 | 1979-06-15 | Procede de preparation de solutions aqueuses stables d'alloxane et solutions en resultant |
| DK303679A DK303679A (da) | 1979-06-15 | 1979-07-19 | Fremgangsmaade til fremstilling af en stabil vandig alloxanoploesning samt en saadan oploesning |
| DE8080400847T DE3071091D1 (en) | 1979-06-15 | 1980-06-11 | Stable aqueous solutions of alloxane |
| EP80400847A EP0021953B1 (fr) | 1979-06-15 | 1980-06-11 | Solutions aqueuses stables d'alloxane |
| US06/159,168 US4292312A (en) | 1979-06-15 | 1980-06-13 | Method for preparing alloxan stable aqueous solutions and solutions resulting therefrom |
| FR8018994A FR2489148A2 (fr) | 1979-06-15 | 1980-09-03 | Procede de preparation de solutions aqueuses stables d'alloxane et solutions en resultant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7915363A FR2459046A1 (fr) | 1979-06-15 | 1979-06-15 | Procede de preparation de solutions aqueuses stables d'alloxane et solutions en resultant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2459046A1 true FR2459046A1 (fr) | 1981-01-09 |
| FR2459046B1 FR2459046B1 (enExample) | 1983-01-07 |
Family
ID=9226665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7915363A Granted FR2459046A1 (fr) | 1979-06-15 | 1979-06-15 | Procede de preparation de solutions aqueuses stables d'alloxane et solutions en resultant |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4292312A (enExample) |
| EP (1) | EP0021953B1 (enExample) |
| DE (1) | DE3071091D1 (enExample) |
| DK (1) | DK303679A (enExample) |
| FR (1) | FR2459046A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0223037A1 (de) * | 1985-10-24 | 1987-05-27 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Phenylbarbitursäuren und deren Herstellung |
| US4816568A (en) * | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
| US5869494A (en) * | 1995-02-13 | 1999-02-09 | Gulliya; Kirpal S. | Uses for barbituric acid analogs |
| EP0809634A4 (en) * | 1995-02-13 | 1998-05-20 | Kirpal S Gulliya | NEW USES FOR BARBITURIC ACID ANALOGS |
| EP1223937A2 (en) * | 1999-10-07 | 2002-07-24 | Novaneuron Inc. | Gene necessary for striatal function, uses thereof, and compounds for modulating same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH277825A (de) * | 1949-03-02 | 1951-09-15 | Coffarom Aktiengesellschaft | Verfahren zur Herstellung von Lävulose enthaltenden Injektionslösungen. |
| FR3743M (fr) * | 1963-06-06 | 1965-12-13 | Pierre Grobon | Soluté alloxanique sous azote cyto-stabilisant anti-cancéreux. application de la diabéto-thérapie alloxanique. |
| US3637640A (en) * | 1970-05-04 | 1972-01-25 | Diagnostic Data Inc | Orgotein stabilized with saccharide process and products |
| US3728454A (en) * | 1970-08-14 | 1973-04-17 | Gates Rubber Co | Alloxan compounds as antibacterial and antifungal agents |
| JPS5512046B2 (enExample) * | 1972-05-10 | 1980-03-29 |
-
1979
- 1979-06-15 FR FR7915363A patent/FR2459046A1/fr active Granted
- 1979-07-19 DK DK303679A patent/DK303679A/da not_active Application Discontinuation
-
1980
- 1980-06-11 DE DE8080400847T patent/DE3071091D1/de not_active Expired
- 1980-06-11 EP EP80400847A patent/EP0021953B1/fr not_active Expired
- 1980-06-13 US US06/159,168 patent/US4292312A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US4292312A (en) | 1981-09-29 |
| FR2459046B1 (enExample) | 1983-01-07 |
| DK303679A (da) | 1980-12-16 |
| DE3071091D1 (en) | 1985-10-24 |
| EP0021953A1 (fr) | 1981-01-07 |
| EP0021953B1 (fr) | 1985-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2233924C (fr) | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation | |
| BE1000253A3 (fr) | Preparation pharmaceutique stable contenant un facteur de stimulation des colonies de granulocytes et procede pour la produire. | |
| FR2853547A1 (fr) | Compositions pharmaceutiques injectables contenant de la piperacilline et du tazobactame, et procede pour leur production | |
| EP2482851B1 (fr) | Formulation liquide, stable, prete a l'emploi de ketoprofene | |
| EP1207875B1 (fr) | Preparation pharmaceutique stable d'oxaliplatine pour administration par voie parenterale | |
| EP1265612B1 (en) | Pharmaceutical composition comprising pemetrexed together with monothioglycerol, l-cystein or thioglycolic acid | |
| EA008908B1 (ru) | Инъецируемый жидкий состав парацетамола | |
| FR2459046A1 (fr) | Procede de preparation de solutions aqueuses stables d'alloxane et solutions en resultant | |
| CA2551493C (fr) | Composition pharmaceutique de vinflunine destinee a une administration parenterale, procede de preparation et utilisation | |
| FR2460672A1 (fr) | Preparation de poudre d'acetylsalicylate pour injection | |
| JP2009543851A (ja) | 注入可能なパラセタモール液剤 | |
| MX2011001867A (es) | Formulaciones de canfosfamida y su preparacion. | |
| EP0830144B1 (fr) | Compositions pulverulentes et solubles dans l'eau et leurs applications | |
| FR2461463A1 (fr) | Procede de preparation d'eaux minerales ferrugineuses, eaux minerales obtenues par ce procede et leurs applications therapeutiques | |
| WO2001026622A1 (fr) | Comprime effervescent pour le reperage d'animaux sous traitement, procede de fabrication correspondant, et procede de traitement d'une solution aqueuse | |
| FR2862872A1 (fr) | Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol. | |
| EP0439187A2 (en) | Antioxidant composition in vivo comprising enol form delta-lactone of diketogulonic acid | |
| BE814398A (fr) | Composition solide a base d'enzyme | |
| JP2007091674A (ja) | 注射用の医薬組成物 | |
| CN116251057A (zh) | 一种硝酸异山梨酯注射液及其制备方法 | |
| GR1010637B (el) | Σταθερο υδατικο διαλυμα παρακεταμολης για χρηση σε ενδοφλεβια εγχυση | |
| BE887220A (fr) | Compositions antitumeurs | |
| JPH1045791A (ja) | ヒト用注射薬としての一部凍結乾燥によるフルクトース−１，６−ジホスフェート（ｆｄｐ） | |
| UA72578C2 (en) | Pharmaceutical composition comprising pemetrexed in combination with monothioglycerol, l-cysteine or thioglycolic acid | |
| CH397955A (fr) | Procédé de fabrication d'une préparation corticotropique à action prolongée |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |